These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29254937)

  • 1. Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients.
    Korde LA; Doody DR; Hsu L; Porter PL; Malone KE
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):165-173. PubMed ID: 29254937
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    Lancet; 2015 Oct; 386(10001):1353-1361. PubMed ID: 26211824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
    Monsees GM; Malone KE; Tang MT; Newcomb PA; Li CI
    J Natl Cancer Inst; 2011 Dec; 103(23):1752-60. PubMed ID: 22021667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
    Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.
    Ethier JL; Prince RM; Amir E
    Curr Oncol Rep; 2017 Mar; 19(3):15. PubMed ID: 28251493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates and breast cancer prevention.
    Chlebowski RT; Col N
    Anticancer Agents Med Chem; 2012 Feb; 12(2):144-50. PubMed ID: 21864227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
    Lipton A; Chapman JW; Leitzel K; Garg A; Pritchard KI; Ingle JN; Budd GT; Ellis MJ; Sledge GW; Rabaglio M; Han L; Elliott CR; Shepherd LE; Goss PE; Ali SM
    Cancer; 2017 Jul; 123(13):2444-2451. PubMed ID: 28464211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Bisphosphonates in Breast Cancer Therapy.
    Goldvaser H; Amir E
    Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
    Chlebowski RT; Chen Z; Cauley JA; Anderson G; Rodabough RJ; McTiernan A; Lane DS; Manson JE; Snetselaar L; Yasmeen S; O'Sullivan MJ; Safford M; Hendrix SL; Wallace RB
    J Clin Oncol; 2010 Aug; 28(22):3582-90. PubMed ID: 20567009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.
    Mauri D; Valachis A; Polyzos NP; Tsali L; Mavroudis D; Georgoulias V; Casazza G
    J Natl Compr Canc Netw; 2010 Mar; 8(3):279-86. PubMed ID: 20202461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
    Nahleh Z; Abrams J; Bhargaval A; Nirmal K; Graff JJ
    Clin Breast Cancer; 2010 Dec; 10(6):459-64. PubMed ID: 21147689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
    Costa L
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany.
    Fick EM; Katalinic A; Waldmann A
    Cancer Res Treat; 2015 Oct; 47(4):747-56. PubMed ID: 25672584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.
    Kwan ML; Shi JM; Habel LA; Song J; Chung JW; Avila CC; Schottinger JE; Cheetham TC; Fletcher SW; Haque R
    Breast Cancer Res Treat; 2016 Apr; 156(2):379-89. PubMed ID: 27002508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
    van Hellemond IEG; Smorenburg CH; Peer PGM; Swinkels ACP; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Roos WK; Linn SC; Imholz ALT; de Boer M; Tjan-Heijnen VCG;
    Breast Cancer Res Treat; 2020 Apr; 180(3):675-685. PubMed ID: 32124136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.